VTGN Stock Analysis: Buy, Sell, or Hold?
VTGN - Vistagen Therapeutics, Inc. Common Stock
$0.56
-0.02 (-3.43%)
▼
5d:
-10.25%
30d:
-10.02%
90d:
-7.42%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Jun 16, 2026
12d
Get Alerted When VTGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: VTGN is down 10.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: VTGN is down 10.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: VTGN is currently trading at $0.56, which is considered oversold relative to its 30-day fair value range of $0.60 to $0.64.
Technical Outlook: Technically, VTGN is showing support break momentum. The price is currently testing key support at $0.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $0.97 (+72.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VTGN is showing support break momentum. The price is currently testing key support at $0.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $0.97 (+72.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.60 -
$0.64
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 72.6% below Wall St target ($0.97)
- WARNING: Recommendation downgraded due to -10.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.60 -
$0.64
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.55
Resistance Level
$0.68
Current Trend
Support Break
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.57
Wall Street Target
$0.97
(+72.6%)
Revenue Growth (YoY)
29.5%
Share & Embed Analysis
Last updated: June 03, 2026 6:18 PM ET
Data refreshes hourly during market hours. Next update: 7:18 PM
Data refreshes hourly during market hours. Next update: 7:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VTGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 55 HOLD |
